

# Acquisition and Reconstruction Techniques for Coronary CT Angiography

## Arineta Scanner Platforms

Edited and Approved by

Jonathon Leipsic MD FSCCT  
Past-President Society of Cardiovascular CT

# Table of Contents

1. Overview .....	3
2. Introduction .....	4
Importance of Heart Rate Control .....	4
Importance of Nitrates .....	4
Selection of Tube Current and Potential.....	5
3. Reference Protocol: Arineta - SpotLight & SpotLight Duo.....	6
1. Scout.....	6
2. ECG-gated Axial Data Acquisition of the Coronaries/Heart Smart Prep.....	6
3. Scan Parameters .....	7
4. Contrast Protocol.....	8
5. Recommended mA and kV based on the patient's BMI: .....	8
9. Bibliography.....	9

# 1. Overview

Coronary computed tomography angiography (CCTA) is a non-invasive diagnostic for detecting coronary artery disease (CAD). CCTA is increasingly utilized in clinical practice for evaluating coronary anatomy for obstructive disease and plaque.

It is, however, imperative that artifact free CCTA image data is obtained in order for it to be successfully analyzed for anatomic assessment and/or to act as adequate input for adjunct analyses such as physiologic simulations. Data acquisition strategies and scanning protocols may vary depending on scanner manufacturer, system, and institutional preferences. This document provides references for reliable image acquisition for CCTA.

## 2. Introduction

Image acquisition in computed tomography is governed ultimately by the principle of As Low As Reasonably Achievable (ALARA). In the first 10 years of CCTA, the focus was almost exclusively on the detection of anatomical stenosis in low to intermediate risk patients. With the evolution of technology, the clinical utility of CCTA has extended beyond stenosis assessment to atherosclerosis characterization, the evaluation of structural heart disease, and the functional and physiological assessment of coronary stenoses. Recently the SCCT acquisition guidelines were updated and provide an excellent reference for Cardiac CT imaging specialists to help optimize their scan protocols. That being said, given the growing information that is provided from cardiac CT, the imaging requirements have evolved and require tailoring to meet the clinical indication. The purpose of this white paper is to highlight the parameters and image acquisition protocols that are important to help optimize image quality, provide accurate representation of anatomy and thus enable quantitative CT.

### **Importance of Heart Rate Control**

With the advancements in scanner technology, the necessary requirement for heart rate reduction has decreased over time. The demands for a low and steady heart rate to ensure diagnostic image quality may not be what they once were but best practice remains to optimize image quality through heart rate control. SCCT guidelines recommend performing CCTA with heart rates below 60 bpm.

In addition, CCTA no longer simply provides stenosis evaluation but needs to enable the interpreting physician to identify and characterize plaque and, following the identification of a stenosis, to perform functional or physiologic evaluation. As a result, while latest generation CT scanners may enable diagnostic image quality at higher heart rates, there remains meaningful image quality benefits from heart rate reduction. In addition, lower heart rates allow the use of lower dose scan acquisitions that are not possible at higher heart rates. Heart rate control strategies are well established and the appropriate strategy is dependent on a number of variables including available medications, setting of practice and site preference. For recommendations please refer to the recently updated SCCT acquisition guidelines.

### **Importance of Nitrates**

Nitrates as smooth muscle dilators have direct effect on coronary vasodilation and result in tangible enlargement of coronary size. As such, similar to invasive coronary catheterization, nitroglycerine (glyceryl trinitrate) should be administered prior to CCTA to optimize image quality and enable the most accurate stenosis evaluation. A commonly used regimen is 400-800 µg of sublingual nitroglycerin administered as either sublingual tablets or a metered lingual spray (commonly 1-2 tablets or 1-2 sprays) prior to the CCTA. While the evidence is modest and there is no randomized data, both a higher dose and administration via spray are becoming increasingly preferred in clinical practice and have been shown to help optimize coronary evaluation.

## **Selection of Tube Current and Potential**

The scan parameters used for any cardiac CT should be tailored to the individual patient but also the intended application. The image quality issues with the greatest impact on the interpretability of CT are misalignment and image noise. As such, care must be given to ensure that image noise properties are appropriate and adequate for accurate lumen segmentation. To do so, tube current and potential should be selected carefully, guided by chest wall circumference, the iodine concentration of the intravenous contrast medium, and whether iterative reconstruction is available or not.

Iterative reconstruction (IR) has the ability to reduce image noise in CT without compromising the diagnostic quality of the CT image dataset, which permits a significant reduction in effective radiation dose. In current clinical practice, IR has enabled a significant reduction in radiation dose by allowing for a reduction in tube current and is now increasingly available across all cardiac capable CT scanners. IR commonly takes the form of a blended reconstruction of IR and filtered back projection (FBP). While a very helpful tool, care should be given when using a very high percentage of IR for quantitative CT analysis due to the potential impact on vessel segmentation.

# 3. Reference Protocol: Arineta - SpotLight & SpotLight Duo

## 1. Scout

General	Data Acquisition	Comments
Volume scout covering the heart and coronaries	<ul style="list-style-type: none"> <li>• Scan Range: 260 mm</li> <li>• Start: Superior 5 mm</li> <li>• End: Inferior 245 mm</li> <li>• Tube Current: 50 mA</li> <li>• Tube Voltage: 80 kV</li> <li>• ECG Trace: On</li> <li>• Scout Plane: Volume</li> <li>• Auto Voice: (Breath hold command)</li> </ul>	Take note on the scouts to ensure that the patient is positioned within 2 cm of isocenter to allow for best image quality. Adjust table height and lateral table location to adjust isocenter location if more than 2 cm off.

## 2. ECG-gated Axial Data Acquisition of the Coronaries/Heart Smart Prep

General	Data Acquisition	Comments
<ul style="list-style-type: none"> <li>• Bolus tracking to automatically trigger the diagnostic scan acquisition based on the HU reading in the ROI reaching the prescribed enhancement threshold</li> <li>• Slice location: approximately 2 cm below the carina</li> <li>• ROI location: Descending aorta</li> </ul>	<ul style="list-style-type: none"> <li>• Monitoring Delay: 8 sec</li> <li>• Monitoring Inter Scan Delay: 2 sec</li> <li>• Tube Voltage: 100 kV</li> <li>• Tube current: 70 mA</li> <li>• Diagnostic Delay: 8 sec</li> <li>• Threshold: 120 HU Enhancement</li> <li>• Auto Voice: (Breath hold command): "Breathe in and hold your breath"</li> </ul>	<p>The effective ('diagnostic') delay between reaching the threshold and the start of the subsequent data acquisition is the combined time comprising (breath hold commands) and the time needed for table movement</p> <p>NOTE: the kV and Rotation Time parameters in the diagnostic scan tasks have to be the same.</p>

### 3. Scan Parameters

General	Settings	Comments
<ul style="list-style-type: none"> <li>ECG-gated axial data acquisition of the heart</li> <li>Scan range beginning 2 cm below the carina to the base of the heart for routine CCTA without previous CABG procedure</li> <li>mA set achieve best IQ</li> </ul>	<p><b>Anatomy Selection:</b></p> <ul style="list-style-type: none"> <li>Start location: ~2cm below the carina</li> <li>End location: base of heart</li> <li>SFOV: 25 cm</li> <li>DFOV: 25 cm</li> </ul> <p><b>ECG &amp; Gating</b></p> <ul style="list-style-type: none"> <li>HR Variation Allowance: 1 BPM</li> <li>Arrhythmia Retriggering: On</li> </ul> <p><b>kV and mA</b></p> <ul style="list-style-type: none"> <li>kV: 80-140 (see table on page 11)</li> <li>mA: 400-600 (see table on page 11)</li> <li>(Breath hold command):</li> <li>Post voice Delay Time: 5 seconds (Together with Breath hold command and table movement, this results in a diagnostic delay 7.7 sec)</li> </ul> <p><b>Scan Type:</b></p> <ul style="list-style-type: none"> <li>Scan Type: Cardiac</li> <li>Hi-Res Mode: Off</li> <li>Rotation Speed: 0.24 seconds (slower for very large patients with a low heart rate)</li> </ul> <p><b>Coverage Speed:</b></p> <ul style="list-style-type: none"> <li>Table Positions: One</li> <li>Detector Coverage:</li> <li>Number of Passes: 1</li> </ul> <p><b>Primary Recon:</b></p> <ul style="list-style-type: none"> <li>Thickness: 0.5 mm</li> <li>Recon Type: Std CV</li> <li>DLIR-MBAF2-MED</li> </ul> <p><b>Secondary Recon:</b></p> <ul style="list-style-type: none"> <li>Off line</li> </ul>	<p>Use the ECG trace information within the last test breath hold to determine target phases for reconstruction.</p> <p>For example, if the HR was steady at 65 beats per minute the acquisition window will be set to acquire a phase range of 70-80% of the R to R</p> <p>Recommendation: SnapShot Freeze is an optional feature that should be turned on if HR is &gt;60 BPM. Reconstruct off line.</p>

#### 4. Contrast Protocol

General	Specific	
<ul style="list-style-type: none"> <li>Single contrast application for both the ECG-gated axial CTA of the aortic root/heart and the CTA of the thorax/abdomen/pelvis</li> <li>Biphasic administration protocol with pure contrast followed by a saline chaser</li> <li>Placement of IV access per hospital protocol (an 18-gauge IV typically provides the highest safety)</li> <li>Automated contrast injection using a dual-cylinder injector</li> </ul>	<ul style="list-style-type: none"> <li>For normal weighted patients and an iodinated contrast agent with 350-370 mg/ml apply 70 ml contrast at 5 ml/sec, followed by 30 ml saline at 5 ml/sec;</li> </ul>	<ul style="list-style-type: none"> <li>For large patients and an iodinated contrast agent with 350-370 mg/ml apply 70 ml contrast at 6 ml/sec, followed by 50 ml saline at 6 ml/sec</li> </ul>
	350-370 mg/ml 5 ml/sec of 70 ml contrast 5 ml/sec of 50 ml saline	350-370 mg/ml 6 ml/sec of 70 ml \contrast 6 ml/sec of 50 ml saline

#### 5. Recommended mA and kV based on the patient's BMI:

BMI	kV	mA	Gantry Rotation	Recon
<21	100	350	0.24	DLIR & MBAF2-MED
21-23	100	400	0.24	DLIR & MBAF2-MED
23-25	100	450	0.24	DLIR & MBAF2-MED
25-28	100	500	0.24	DLIR & MBAF2-MED
29-34	120	600	0.24	DLIR & MBAF2-MED
>35*	120	600	0.33	DLIR & MBAF2-MED

\*Heart rate >60 BPM for patients with high BMI may result in images with a high degree of coronary motion



# 9. Bibliography

1. Dewey M, Hoffmann H, Hamm B. Multislice CT coronary angiography: effect of sublingual nitroglycerine on the diameter of coronary arteries. *RoFo: Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin*. 2006;178(6):600-4.
2. Decramer I, Vanhoenacker PK, Sarno G, Van Hoe L, Bladt O, Wijns W, et al. Effects of sublingual nitroglycerin on coronary lumen diameter and number of visualized septal branches on 64-MDCT angiography. *American Journal of Roentgenology*. 2008;190(1):219-25.
3. Laslett LJ, Baker L. Sublingual nitroglycerin administered by spray versus tablet: comparative timing of hemodynamic effects. *Cardiology*. 1990;77(4):303-10.
4. Bachmann KF, Gansser RE. Nitroglycerin oral spray: evaluation of its coronary artery dilative action by quantitative angiography. *The American journal of cardiology*. 1988;61(9):7E-11E.
5. Sato K, et al. Optimal starting time of acquisition and feasibility of complementary administration of nitroglycerin with intravenous beta-blocker in multislice computed tomography. *J CCT*. 2009;33(2):193
6. Abbara S, Blanke P, Maroules CD, Cheezum M, Choi AD, Han BK, Marwan M, Naoum C, Norgaard BL, Rubinshtein R, Schoenhagen P, Villines T, Leipsic J. SCCT guidelines for the performance and acquisition of coronary computed tomographic angiography: A report of the society of Cardiovascular Computed Tomography Guidelines Committee: Endorsed by the North American Society for Cardiovascular Imaging (NASCI). *J Cardiovasc Comput Tomogr*. 2016 Oct 12. pii: S1934-5925(16)30239-8.
7. Leipsic J, Abbara S, Achenbach S, Cury R, Earls JP, Mancini GJ, et al. SCCT guidelines for the interpretation and reporting of coronary CT angiography: a report of the Society of Cardiovascular Computed Tomography Guidelines Committee. *Journal of cardiovascular computed tomography*. 2014;8(5):342-58.
8. Budoff MJ, Dowe D, Jollis JG, Gitter M, Sutherland J, Halamert E, et al. Diagnostic performance of 64-multidetector row coronary computed tomographic angiography for evaluation of coronary artery stenosis in individuals without known coronary artery disease: results from the prospective multicenter ACCURACY (Assessment by Coronary Computed Tomographic Angiography of Individuals Undergoing Invasive Coronary Angiography) trial. *Journal of the American College of Cardiology*. 2008;52(21):1724-32.
9. Meijboom WB, Meijs MF, Schuijf JD, Cramer MJ, Mollet NR, van Mieghem CA, et al. Diagnostic accuracy of 64-slice computed tomography coronary angiography: a prospective, multicenter, multivendor study. *Journal of the American College of Cardiology*. 2008;52(25):2135-44.
10. Miller JM, Rochitte CE, Dewey M, Arbab-Zadeh A, Niinuma H, Gottlieb I, et al. Diagnostic performance of coronary angiography by 64-row CT. *The New England journal of medicine*. 2008;359(22):2324-36.
11. Min JK, Shaw LJ, Devereux RB, Okin PM, Weinsaft JW, Russo DJ, et al. Prognostic value of multidetector coronary computed tomographic angiography for prediction of all-cause mortality. *Journal of the American College of Cardiology*. 2007;50(12):1161-70.
12. Min JK, Dunning A, Lin FY, Achenbach S, Al-Mallah M, Budoff MJ, et al. Age- and sex-related differences in all-cause mortality risk based on coronary computed tomography angiography findings results from the International Multicenter CONFIRM (Coronary CT Angiography Evaluation for Clinical Outcomes: An International Multicenter Registry) of 23,854 patients without known coronary artery disease. *Journal of the American College of Cardiology*. 2011;58(8):849-60.
13. Villines TC, Hulten EA, Shaw LJ, Goyal M, Dunning A, Achenbach S, et al. Prevalence and severity of coronary artery disease and adverse events among symptomatic patients with coronary artery calcification scores of zero undergoing coronary computed tomography angiography: results from the CONFIRM (Coronary CT Angiography Evaluation for Clinical Outcomes: An International Multicenter) registry. *Journal of the American College of Cardiology*. 2011;58(24):2533-40.
14. Leipsic J, Taylor CM, Gransar H, Shaw LJ, Ahmadi A, Thompson A, et al. Sex-based prognostic implications of nonobstructive coronary artery disease: results from the international multicenter CONFIRM study. *Radiology*. 2014;273(2):393-400.
15. Taylor AJ, Cerqueira M, Hodgson JM, Mark D, Min J, O'Gara P, et al. ACCF/SCCT/ACR/AHA/ASE/ASNC/NASCI/SCAI/SCMR 2010 appropriate use criteria for cardiac computed tomography. A report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, the Society of Cardiovascular Computed Tomography, the American College of Radiology, the American Heart Association, the American Society of Echocardiography, the American Society of Nuclear Cardiology, the North American Society for Cardiovascular Imaging, the Society for Cardiovascular Angiography and Interventions, and the Society for Cardiovascular Magnetic Resonance. *Journal of the American College of Cardiology*. 2010;56(22):1864-94.

16. Jacobs JE, Box LM, Desjardins B, Fishman EK, Larson PA, Schoepf J, et al. ACR practice guideline for the performance and interpretation of cardiac computed tomography (CT). *Journal of the American College of Radiology* : JACR. 2006;3(9):677-85.
17. Halliburton SS, Abbara S, Chen MY, Gentry R, Mahesh M, Raff GL, et al. SCCT guidelines on radiation dose and dose-optimization strategies in cardiovascular CT. *Journal of cardiovascular computed tomography*. 2011;5(4):198-224.
18. Valentin J. Pregnancy and medical radiation: ICRP publication 84. . *Ann ICRP* 2000(30(1)):1-39.
19. Chen MM, Coakley FV, Kaimal A, Laros RK, Jr. Guidelines for computed tomography and magnetic resonance imaging use during pregnancy and lactation. *Obstet Gynecol*. 2008;112(2 Pt 1):333-340.
20. Woussen S1, Lopez-Rendon X, Vanbeckevoort D, Bosmans H, Oyen R, Zanca F. Clinical indications and radiation doses to the conceptus associated with CT imaging in pregnancy: a retrospective study. *Eur Radiol*. 2015 Jul 23.
21. Webb JA, Thomsen HS, Morcos SK, Members of Contrast Media Safety Committee of European Society of Urogenital R. The use of iodinated and gadolinium contrast media during pregnancy and lactation. *European radiology*. 2005;15(6):1234-40.
22. Rubin G, Bluemke D, Duerinckx A, Flamm S, Grist T, Jacobs J, et al. ACR Committee on Cardiac Imaging. Practice guideline for the performance and interpretation of cardiac computed tomography (CT). (Res. 10, 16g, 17, 34, 35, 36 – 2006) In: *Practice Guidelines and Technical Standards*. Reston, VA: American College of Radiology. 2008;421-30.
23. Greenberger P, Patterson R. Prednisone-diphenhydramine regimen prior to use of radiographic contrast media. *The Journal of allergy and clinical immunology*. 1979;63(4):295.
24. Zeiher AM, Schachinger V, Minners J. Long-term cigarette smoking impairs endothelium-dependent coronary arterial vasodilator function. *Circulation*. 1995;92(5):1094-100.
25. Quillen JE, Rossen JD, Oskarsson HJ, Minor RL, Jr., Lopez AG, Winniford MD. Acute effect of cigarette smoking on the coronary circulation: constriction of epicardial and resistance vessels. *Journal of the American College of Cardiology*. 1993;22(3):642-7.
26. Elicker BM, Cypel YS, Weinreb JC. IV contrast administration for CT: a survey of practices for the screening and prevention of contrast nephropathy. *AJR American journal of roentgenology*. 2006;186(6):1651-8.
27. Lee JK, Warshauer DM, Bush WH, Jr., McClennan BL, Choyke PL. Determination of serum creatinine level before intravenous administration of iodinated contrast medium. A survey. *Investigative radiology*. 1995;30(12):700-5.
28. Owen RJ, Hiremath S, Myers A, Fraser-Hill M, Barrett BJ. Canadian Association of Radiologists consensus guidelines for the prevention of contrast-induced nephropathy: update 2012. *Canadian Association of Radiologists journal = Journal l'Association canadienne des radiologistes*. 2014;65(2):96-105.
29. Owen at al. Canadian Association of Radiologists consensus guidelines for the prevention of contrast-induced nephropathy. *Can Assoc Radiol J*. 2014 May;65(2):96-105
30. Briguori C, Airoidi F, D'Andrea D, Bonizzoni E, Morici N, Focaccio A, et al. Renal Insufficiency Following Contrast Media Administration Trial (REMEDIAL): a randomized comparison of 3 preventive strategies. *Circulation*. 2007;115(10):1211-7.
31. Briguori C, Colombo A, Violante A, Balestrieri P, Manganelli F, Paolo Elia P, et al. Standard vs double dose of N-acetylcysteine to prevent contrast agent associated nephrotoxicity. *European heart journal*. 2004;25(3):206-11.
32. Lee PT, Chou KJ, Liu CP, Mar GY, Chen CL, Hsu CY, et al. Renal protection for coronary angiography in advanced renal failure patients by prophylactic hemodialysis. A randomized controlled trial. *Journal of the American College of Cardiology*. 2007;50(11):1015-20.
33. Marenzi G, Assanelli E, Marana I, Lauri G, Campodonico J, Grazi M, et al. N-acetylcysteine and contrast-induced nephropathy in primary angioplasty. *The New England journal of medicine*. 2006;354(26):2773-82.
34. McDonald R, Mdcondal J, Bida Jet al *Intravenous Contrast Material–induced Nephropathy*:
35. Causal or Coincident Phenomenon?. *Radiology* Volume 267: Number 1—April 2013
36. Newhouse JH, Kho D, Rao QA, Starren J. Frequency of serum creatinine changes in the absence of iodinated contrast material: implications for studies of contrast nephrotoxicity. *AJR American journal of roentgenology*. 2008;191(2):376-82.
37. McDonald RJ, McDonald JS, Carter RE, Hartman RP, Katzberg RW, Kallmes DF, et al. Intravenous contrast material exposure is not an independent risk factor for dialysis or mortality. *Radiology*. 2014;273(3):714-25.
38. Owen RJ, Hiremath S, Myers A, Fraser-Hill M, Barrett BJ. Canadian Association of Radiologists consensus guidelines for the prevention of contrast-induced nephropathy: update 2012. *Canadian Association of Radiologists journal = Journal l'Association canadienne des radiologistes*. 2014;65(2):96-105.
39. Ahuja TS, Niaz N, Agraharkar M. Contrast-induced nephrotoxicity in renal allograft recipients. *Clinical nephrology*. 2000;54(1):11-4.

40. Brodoefel H, Reimann A, Heuschmid M, Kuttner A, Beck T, Burgstahler C, et al. Non-invasive coronary angiography with 16-slice spiral computed tomography: image quality in patients with high heart rates. *European radiology*. 2006;16(7):1434-41.
41. Cademartiri F, Mollet NR, Runza G, Belgrano M, Malagutti P, Meijboom BW, et al. Diagnostic accuracy of multislice computed tomography coronary angiography is improved at low heart rates. *The international journal of cardiovascular imaging*. 2006;22(1):101-5; discussion 7-9.
42. Achenbach S, Manolopoulos M, Schuhback A, Ropers D, Rixe J, Schneider C, et al. Influence of heart rate and phase of the cardiac cycle on the occurrence of motion artifact in dual-source CT angiography of the coronary arteries. *Journal of cardiovascular computed tomography*. 2012;6(2):91-8.
43. Le Jemtel TH, Padeletti M, Jelic S. Diagnostic and therapeutic challenges in patients with coexistent chronic obstructive pulmonary disease and chronic heart failure. *Journal of the American College of Cardiology*. 2007;49(2):171-80.
44. Maffei E, Palumbo AA, Martini C, Tedeschi C, Tarantini G, Seitun S, et al. "In-house" pharmacological management for computed tomography coronary angiography: heart rate reduction, timing and safety of different drugs used during patient preparation. *European radiology*. 2009;19(12):2931-40.
45. Roberts WT, Wright AR, Timmis JB, Timmis AD. Safety and efficacy of a rate control protocol for cardiac CT. *The British journal of radiology*. 2009;82(976):267-71.
46. Earls et al JCCT Metoprolol
47. Sadamatsu K, Koide S, Nakano K, Yoshida K. Heart rate control with single administration of a long-acting beta-blocker at bedtime before coronary computed tomography angiography. *Journal of cardiology*. 2015;65(4):293-7.
48. Clayton B, Raju V, Roobottom C, Morgan-Hughes G. Safety of intravenous beta-adrenoceptor blockers for computed tomographic coronary angiography. *British journal of clinical pharmacology*. 2015;79(3):533-6.
49. Kassamali RH, Kim DH, Patel H, Raichura N, Hoey ET, Hodson J, et al. Safety of an i.v. beta-adrenergic blockade protocol for heart rate optimization before coronary CT angiography. *AJR American journal of roentgenology*. 2014;203(4):759-62.
50. Wang JD, Zhang HW, Xin Q, Yang JJ, Sun ZJ, Liu HB, et al. Safety and efficacy of intravenous esmolol before prospective electrocardiogram-triggered high-pitch spiral acquisition for computed tomography coronary angiography. *Journal of geriatric cardiology : JGC*. 2014;11(1):39-43.
51. Dobre D, Borer JS, Fox K, Swedberg K, Adams KF, Cleland JG, et al. Heart rate: a prognostic factor and therapeutic target in chronic heart failure. The distinct roles of drugs with heart rate-lowering properties. *European journal of heart failure*. 2014;16(1):76-85.
52. Pichler P, Pichler-Cetin E, Vertesich M, Mendel H, Sochor H, Dock W, et al. Ivabradine versus metoprolol for heart rate reduction before coronary computed tomography angiography. *The American journal of cardiology*. 2012;109(2):169-73.
53. Celik O, Atasoy MM, Erturk M, Yalcin AA, Aksu HU, Diker M, et al. Comparison of different strategies of ivabradine premedication for heart rate reduction before coronary computed tomography angiography. *Journal of cardiovascular computed tomography*. 2014;8(1):77-82.
54. Guaricci AI, Schuijf JD, Cademartiri F, Brunetti ND, Montrone D, Maffei E, et al. Incremental value and safety of oral ivabradine for heart rate reduction in computed tomography coronary angiography. *International journal of cardiology*. 2012;156(1):28-33.
55. Guaricci AI, Maffei E, Brunetti ND, Montrone D, Di Biase L, Tedeschi C, et al. Heart rate control with oral ivabradine in computed tomography coronary angiography: a randomized comparison of 7.5 mg vs 5 mg regimen. *International journal of cardiology*. 2013;168(1):362-8.
56. Adile KK, Kapoor A, Jain SK, Gupta A, Kumar S, Tewari S, et al. Safety and efficacy of oral ivabradine as a heart rate-reducing agent in patients undergoing CT coronary angiography. *The British journal of radiology*. 2012;85(1016):e424-8.
57. Cademartiri F, Garot J, Tendra M, Zamorano JL. Intravenous ivabradine for control of heart rate during coronary CT angiography: A randomized, double-blind, placebo-controlled trial. *Journal of cardiovascular computed tomography*. 2015;9(4):286-94.
58. Parker JD, Parker JO. Nitrate therapy for stable angina pectoris. *The New England journal of medicine*. 1998;338(8):520-31.
59. Dewey M, Hoffmann H, Hamm B. Multislice CT coronary angiography: effect of sublingual nitroglycerine on the diameter of coronary arteries. *RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin*. 2006;178(6):600-4.
60. Decramer I, Vanhoenacker PK, Sarno G, Van Hoe L, Bladt O, Wijns W, et al. Effects of sublingual nitroglycerin on coronary lumen diameter and number of visualized septal branches on 64-MDCT angiography. *AJR American journal of roentgenology*. 2008;190(1):219-25.
61. Laslett LJ, Baker L. Sublingual nitroglycerin administered by spray versus tablet: comparative timing of hemodynamic effects. *Cardiology*. 1990;77(4):303-10.

62. Bachmann KF, Gansser RE. Nitroglycerin oral spray: evaluation of its coronary artery dilative action by quantitative angiography. *The American journal of cardiology*. 1988;61(9):7E-11E.
63. Sato K, et al. Optimal starting time of acquisition and feasibility of complementary administration of nitroglycerin with intravenous beta-blocker in multislice computed tomography. *JCCT*. 2009;33(2):193
64. Chun EJ et al J. Effects of nitroglycerin on the diagnostic accuracy of electrocardiogram-gated coronary computed tomography angiography. *JCCT*. 2008;32(1):86-92
65. Wang G, Vannier MW. Spatial variation of section sensitivity profile in spiral computed tomography. *Medical physics*. 1994;21(9):1491-7.
66. Ohnesorge B, Flohr T, Becker C, Kopp AF, Schoepf UJ, Baum U, et al. Cardiac imaging by means of electrocardiographically gated multisection spiral CT: initial experience. *Radiology*. 2000;217(2):564-71.
67. Halliburton SS, Abbara S. Practical tips and tricks in cardiovascular computed tomography: patient preparation for optimization of cardiovascular CT data acquisition. *Journal of cardiovascular computed tomography*. 2007;1(1):62-5.
68. Bae KT, Tran HQ, Heiken JP. Multiphasic injection method for uniform prolonged vascular enhancement at CT angiography: pharmacokinetic analysis and experimental porcine model. *Radiology*. 2000;216(3):872-80.
69. Fleischmann D, Rubin GD, Bankier AA, Hittmair K. Improved uniformity of aortic enhancement with customized contrast medium injection protocols at CT angiography. *Radiology*. 2000;214(2):363-71.
70. Haage P, Schmitz-Rode T, Hubner D, Piroth W, Gunther RW. Reduction of contrast material dose and artifacts by a saline flush using a double power injector in helical CT of the thorax. *AJR American journal of roentgenology*. 2000;174(4):1049-53.
71. Hopper KD, Mosher TJ, Kasales CJ, TenHave TR, Tully DA, Weaver JS. Thoracic spiral CT: delivery of contrast material pushed with injectable saline solution in a power injector. *Radiology*. 1997;205(1):269-71.
72. Raju R, Thompson AG, Lee K, Precious B, Yang TH, Berger A, et al. Reduced iodine load with CT coronary angiography using dual-energy imaging: a prospective randomized trial compared with standard coronary CT angiography. *Journal of cardiovascular computed tomography*. 2014;8(4):282-8.
73. Carrascosa P, Leipsic JA, Capunay C, Deviggiano A, Vallejos J, Goldsmit A, et al. Monochromatic image reconstruction by dual energy imaging allows half iodine load computed tomography coronary angiography. *European journal of radiology*. 2015.
74. Yin WH, Lu B, Gao JB, Li PL, Sun K, Wu ZF, et al. Effect of reduced x-ray tube voltage, low iodine concentration contrast medium, and sinogram-affirmed iterative reconstruction on image quality and radiation dose at coronary CT angiography: results of the prospective multicenter REALISE trial. *Journal of cardiovascular computed tomography*. 2015;9(3):215-24.
75. Hein PA, May J, Rogalla P, Butler C, Hamm B, Lembcke A. Feasibility of contrast material volume reduction in coronary artery imaging using 320-slice volume CT. *European radiology*. 2010;20(6):1337-43.
76. Kim R, et al. Feasibility of 320-row CT coronary angiography using 40 mL...*Eur Radiol*. 2016; Feb 23 (Epub ahead of print).
77. Marwan et al *Radiology High Pitch TAVR*
78. Segal A, Ellis J, Baumgartner B, Choyke P, Cohan R, Costouros N, et al. ACR Committee on Drugs and Contrast Media. Practice guideline for the use of intravascular contrast media. (Res. 38 – 2007) In: *Practice Guidelines and Technical Standards*. Reston, VA: . American College of Radiology. 2008;73-78.
79. Brenner DJ, Doll R, Goodhead DT, Hall EJ, Land CE, Little JB, et al. Cancer risks attributable to low doses of ionizing radiation: assessing what we really know. *Proceedings of the National Academy of Sciences of the United States of America*. 2003;100(24):13761-6.
80. Committee to Assess Health Risks from Exposure to Low Levels of Ionizing Radiation; Nuclear and Radiation Studies Board, Division on Earth and Life Studies, National Research Council of the National Academies. *Health Risks From Exposure to Low Levels of Ionizing Radiation: BEIR VII Phase 2*. Washington, DC: The National Academies Press. 2006.
81. Don S. Radiosensitivity of children: potential for overexposure in CR and DR and magnitude of doses in ordinary radiographic examinations. *Pediatric radiology*. 2004;34 Suppl 3:S167-72; discussion S234-41.
82. Einstein AJ, Henzlova MJ, Rajagopalan S. Estimating risk of cancer associated with radiation exposure from 64-slice computed tomography coronary angiography. *JAMA : the journal of the American Medical Association*. 2007;298(3):317-23.
83. Deseive S, Chen MY, Korosoglou G, Leipsic J, Martuscelli E, Carrascosa P, et al. Prospective Randomized Trial on Radiation Dose Estimates of CT Angiography Applying Iterative Image Reconstruction: The PROTECTION V Study. *JACC Cardiovascular imaging*. 2015;8(8):888-96.
84. Deseive S, Pugliese F, Meave A, Alexanderson E, Martinoff S, Hadamitzky M, et al. Image quality and radiation dose of a prospectively electrocardiography-triggered high-pitch data acquisition strategy for coronary CT angiography: The multicenter, randomized PROTECTION IV study. *Journal of cardiovascular computed tomography*. 2015;9(4):278-85.



85. Hausleiter J, Martinoff S, Hadamitzky M, Martuscelli E, Pschierer I, Feuchtner GM, et al. Image quality and radiation exposure with a low tube voltage protocol for coronary CT angiography results of the PROTECTION II Trial. *JACC Cardiovascular imaging*. 2010;3(11):1113-23.
86. Hausleiter J, Meyer TS, Martuscelli E, Spagnolo P, Yamamoto H, Carrascosa P, et al. Image quality and radiation exposure with prospectively ECG-triggered axial scanning for coronary CT angiography: the multicenter, multivendor, randomized PROTECTION-III study. *JACC Cardiovascular imaging*. 2012;5(5):484-93.
87. Chen MY, et al. Submillisievert median radiation dose for coronary angiography with a second-generation 320-detector row CT scanner in 107 consecutive patients. *Radiology*. 2013 Apr;267(1):76-85. doi: 10.1148/radiol.13122621. Epub 2013 Jan 22.
88. Zhao L, Plank F, Kummann M, Burghard P, Klauser A, Dichtl W, Feuchtner G. Improved non-calcified plaque delineation on coronary CT angiography by sonogram-affirmed iterative reconstruction with different filter strength and relationship with BMI. *Cardiovasc Diagn Ther*. 2015 Apr;5(2):104-12.
89. Task Group on Control of Radiation Dose in Computed T. Managing patient dose in computed tomography. A report of the International Commission on Radiological Protection. *Annals of the ICRP*. 2000;30(4):7-45.
90. Hausleiter J, Meyer T, Hadamitzky M, Huber E, Zankl M, Martinoff S, et al. Radiation dose estimates from cardiac multislice computed tomography in daily practice: impact of different scanning protocols on effective dose estimates. *Circulation*. 2006;113(10):1305-10.
91. Siegel MJ, Schmidt B, Bradley D, Suess C, Hildebolt C. Radiation dose and image quality in pediatric CT: effect of technical factors and phantom size and shape. *Radiology*. 2004;233(2):515-22.
92. Leipsic J, LaBounty TM, Mancini GB, Heilbron B, Taylor C, Johnson MA, et al. A prospective randomized controlled trial to assess the diagnostic performance of reduced tube voltage for coronary CT angiography. *AJR American journal of roentgenology*. 2011;196(4):801-6.
93. Oda S, Utsunomiya D, Funama Y, Yonenaga K, Namimoto T, Nakaura T, et al. A hybrid iterative reconstruction algorithm that improves the image quality of low-tube-voltage coronary CT angiography. *AJR American journal of roentgenology*. 2012;198(5):1126-31.
94. Williams MC, Weir NW, Mirsadraee S, Millar F, Baird A, Minns F, et al. Iterative reconstruction and individualized automatic tube current selection reduce radiation dose while maintaining image quality in 320-multidetector computed tomography coronary angiography. *Clinical radiology*. 2013;68(11):e570-7.
95. Deseive S, Pugliese F, Meave A, Alexanderson E, Martinoff S, Hadamitzky M, et al. Image quality and radiation dose of a prospectively electrocardiography-triggered high-pitch data acquisition strategy for coronary CT angiography: The multicenter, randomized PROTECTION IV study. *Journal of cardiovascular computed tomography*. 2015;9(4):278-85.

This paper is presented as a service to medical personnel by HeartFlow and Arineta. The information in this white paper has been compiled from available literature and best practices from expert users. Although every effort has been made to faithfully convey this information, the editors and publisher cannot be held responsible for their correctness. This paper is not intended to be, and should not be construed as, medical advice. For any use, the product information guides, inserts, and operation manuals of the various CT acquisition devices should be consulted. HeartFlow and the editors disclaim any liability arising directly or indirectly from the use of drugs, devices, techniques, or procedures described in this paper.

**WARNING:** Any references to x-ray exposure, intravenous contrast dosage, and other medication are intended as reference guidelines only. The guidelines in this document do not substitute for the judgment of a trained healthcare provider. Each scan requires medical judgment by the healthcare provider about exposing the patient to ionizing radiation. Use the As Low As Reasonably Achievable (ALARA) radiation dose principle to balance factors such as the patient's condition, size and age; region to be imaged; and diagnostic task.

